Search
Selected Filters
Filter Results
Displaying 231–240 of 270 research results
-
Jun 24, 2016
A Steady Hand in Saving Vision
Subretinal injection is the most common form of delivery for gene therapies currently in clinical trials.
-
Jun 6, 2016
Fighting Blindness Gets Sheepish
Researchers in Israel are developing a gene therapy for achromatopsia that may help both sheep and humans alike.
-
May 5, 2016
ARVO 2016: High-School Sophomore Finds Gene Mutation in Family with Choroideremia
Aditya A. Guru, 16, used whole exome sequencing (WES), an innovative genetic-screening technology, to find the mutation.
-
May 4, 2016
ARVO 2016: Emerging Drug Targets Toxic Build-Up in Stargardt Disease
In August 2015, the biotech company Alkeus launched a multi-center TEASE Phase II clinical trial for the drug ALK-001.
-
May 2, 2016
ARVO 2016: ProgSTAR, FFB-CRI's Stargardt Disease Patient Study, Highlighted
When the study and the reports are completed, the ProgSTAR database will be made available to researchers and companies developing therapies.
-
Apr 28, 2016
ARVO 2016: Choroideremia Gene Therapy in Clinical Trial Continues to Perform Well
Five of six patients in NightStaRx’s choroideremia gene-therapy trial continue to benefit from the treatment.
-
Nov 11, 2015
Past Sun Exposure Increases AMD Risk
Researchers from the University of Cologne in Germany and Radboud University in the Netherlands found that increased sunlight exposure during working life significantly increases risk of AMD later in life.
-
Oct 8, 2015
A Leap Forward: Spark Therapeutics Seeks FDA Approval for its Vision-Restoring Gene Therapy
-
Jul 28, 2015
First AMD Patient Receives Argus II Bionic Retina
A pioneering, 80-year-old named Ray Flynn is the first AMD patient to receive the Argus II, and he is already reporting that he can see things better in his garden.
-
Jun 27, 2015
VISIONS 2015 — Dr. José Sahel Receives Foundation's Most Prestigious Research Honor
For those of us supporting the drive for vision-saving treatments and cures, he’s exactly the type of person we want on our team.